£885.00

The 2026-2031 World Outlook for Mood Stabilizers for Bipolar Disorders

Subjects

Price data last checked 125 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£885 today · cheaper than every other day in the last 10 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 177 days • 177 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 177 days • 1 price levels

Days at Price

Price Analysis

Most common price: £885 (177 days, 100.0%)

Price range: £885 - £885

Price levels: 1 different prices over 177 days

Description

This study covers the world outlook for mood stabilizers for bipolar disorders across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of mood stabilizers for bipolar disorders as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Allergan, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis International, Otsuka Pharmaceutical Company, and Pfizer. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2025).

Product Specifications

Format: paperback
ASIN: B0FLDHCNZW
Category: Books > Subjects
Domain: Amazon UK
Release Date: 04 June 2025
Listed Since: 06 August 2025

The 2026-2031 World Outlook for Mood Stabilizers for Bipolar Disorders

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2025-2030 World Outlook for Mood Stabilizers for Bipolar Disorders

The 2026-2031 World Outlook for High Potency APIs (HPAPIs)

Symptom-Focused Psychiatric Drug Therapy for Managed Care: 12 (Routledge Library Editions: Psychiatry)

Integrating Psychotherapy and Psychopharmacology: A Handbook for Clinicians (Clinical Topics in Psychology and Psychiatry)

Meyler's Side Effects of Psychiatric Drugs

American Psychiatric Association Publishing Textbook of Psychopharmacology: Dsm-5 Edition

Handbook of Clinical Psychopharmacology for Therapists (Tenth Edition)

The 2023-2028 Outlook for Bioengineered Monoclonal Antibodies Protein Drugs in Japan

Stahl's Illustrated Mood Stabilizers

The Therapist's Guide to Psychopharmacology, Third Edition: Working with Patients, Families, and Physicians to Optimize Care

The Therapist's Guide to Psychopharmacology, Third Edition: Working with Patients, Families, and Physicians to Optimize Care

Psychopharmacologie essentielle. Le guide du prescripteur (3e édition française): (traduction de la 6e édition américaine)

Neuro-Psychopharmaka. Ein Therapie-Handbuch

The 2023-2028 World Outlook for Pain-Relieving Lidocaine Patches

Handbook of Practical Psychopharmacology

Pediatric Psychopharmacology Evidence: A Clinician's Guide

Prescribing Mental Health Medication: The Practitioner's Guide

Psychopharmacology Reconsidered: A Concise Guide Exploring the Limits of Diagnosis and Treatment

Mind, Brain, and Drug: An Introduction to Psychopharmacology

Nurses' Clinical Consult to Psychopharmacology

Psychopharmacology

The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs (The Maudsley Prescribing Guidelines Series)

Psychopharmacology Reconsidered: A Concise Guide Exploring the Limits of Diagnosis and Treatment

The 2023-2028 Outlook for Drug Delivery Products for US Zip Codes